Indaptus Therapeutics (INDP) Receives Notice of Allowance for Strategic Patent
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- Kroger cuts same-store sales outlook, keeps earnings guidance
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent
September 15, 2021 7:00 AM EDTNEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company), today announced that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the Companys platform technology.
The patent, titled, Methods of Treatment of Infections Using Bacteria, (Application No. 16/584,644) provides broad protection for the application of the Companys platform technology alone and in combination with standards of care for the treatment and inhibition of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.
... More